pharma news

News

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.

News

Lilly puts up to $2.75bn into Insilico alliance

Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.

News

Recordati gets €10.9bn takeover bid from private equity firm

Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

News

Touchdown for Rocket as its first gene therapy gets US okay

Rocket Pharma has won FDA approval for the first gene therapy for LAD-I, a devastating genetic disorder causing severe vulnerability to infections.

News

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Lilly puts up to $2.75bn into Insilico alliance

Recordati gets €10.9bn takeover bid from private equity firm

Where others missed, AZ's IL-33 drug hits the mark in COPD

Touchdown for Rocket as its first gene therapy gets US okay

Novartis snaps up food allergy firm Excellergy for $2bn

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks